Friday, April 26, 2019 10:53:03 AM
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 01:35:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 01:15:26 PM
- Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 • PR Newswire (US) • 11/14/2024 01:15:00 PM
- Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) • PR Newswire (US) • 11/12/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 12:40:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 12:30:12 PM
- Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 11/11/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2024 10:09:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2024 01:06:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2024 01:03:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 10:27:52 PM
- Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 11/05/2024 02:00:00 PM
- Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin • PR Newswire (US) • 11/04/2024 01:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/25/2024 08:43:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2024 08:16:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 12:40:16 PM
- Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available • PR Newswire (US) • 10/17/2024 12:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 12:30:19 PM
- Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 • PR Newswire (US) • 10/07/2024 12:30:00 PM
- Moleculin to Present at Two Upcoming Investor Conferences • PR Newswire (US) • 10/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 08:30:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 12:00:16 PM
- Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma • PR Newswire (US) • 09/23/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:31:07 PM
- Moleculin Participates in Virtual Investor "What this Means" Segment • PR Newswire (US) • 09/16/2024 12:30:00 PM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM